RD Lawrence Lecture 2013 Stratified approaches to the management of diabetes

Diabetic Medicine

Volumn 31, Issue 4, 2014, Pages 393-398

  Pearson, E ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

DIABETIC PATIENT; GENOMICS; HUMAN; INSULIN SYNTHESIS; METABOLOMICS; METAGENOMICS; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PHENOTYPE; PROTEOMICS; REVIEW; RISK ASSESSMENT; TECHNOLOGY;

ARYL HYDROCARBON HYDROXYLASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PHARMACOGENETICS; PHENOTYPE;

EID: 84896115218     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12391     Document Type: Review

References (26)

1. Lawrence RD. Types of human diabetes. Br Med J 1951; 1: 373-375.
2. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013; 30: 803-817.
3. Palmer JP Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264.
4. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975; 24: 44-53.
5. Owen KR. RD Lawrence lecture 2012. Assessing aetiology in diabetes: how C-peptide, CRP and fucosylation came to the party! Diabet Med 2013; 30: 260-266.
6. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000; 17: 543-545.
7. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362: 1275-1281.
8. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003; 26: 3191-3192.
9. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350: 1838-1849.
10. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R et al. Activating mutations in ABCC8 cause neonatal diabetes mellitus. N Engl J Med 2006; 355: 456-466.
11. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355: 467-477.
12. Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996; 384: 458-460.
13. Rubio-Cabezas O, Ellard S. Diabetes mellitus in neonates and infants: genetic heterogeneity, clinical approach to diagnosis, and therapeutic options. Horm Res Paediatr 2013; 80: 137-146.
14. Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in Type 2 diabetes: a Go-DARTS Study. Clin Pharmacol Ther 2010; 87: 52-56.
15. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431.
16. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 2005; 102: 17923-17928.
17. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005; 20: 379-386.
18. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 2007; 74: 359-371.
19. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 2011 21: 837-850.
20. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43: 117-120.
21. Van Leeuwen N, Nijpels G, Becker M, Deshmukh H, Zhou K, Stricker B et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia. 2012; 55: 1971-1977.
22. Mavrou A, Tsangaris GT, Roma E, Kolialexi A. The ATM gene and ataxia telangiectasia. Anticancer Res 2008; 28: 401-405.
23. Schalch DS, McFarlin DE, Barlow MH. An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med 1970; 282: 1396-1402.
24. National Institute for Health and Clinical Excellence. Clinical guideline 87. Type 2 Diabetes: The Management of Type 2 Diabetes. London: NICE, 2009.
25. Network Scottish Intercollegiate Guidelines. SIGN 116: Management of Diabetes. A national clinical guideline. Edinburgh, UK: SIGN, 2010.
26. Matthews DR, Inzucchi SE. ADA/EASD position statement of the treatment of type 2 diabetes: Reply to Rodbard HW and Jellinger PS (letter), Scheen AJ (letter) and Ceriello A, Gallo M, Gentile S et al. (letter). Diabetologia 2012; 55: 2856-2857.